학술논문
Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up)
Document Type
Article
Author
Source
In: Journal of the American Academy of Dermatology . (Journal of the American Academy of Dermatology, September 2023, 89(3):478-485)
Subject
Language
English
ISSN
10976787
01909622
01909622